A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas

被引：5
|
作者：
Gay, Carl M.
Stewart, C. Allison
Frumovitz, Michael
Fujimoto, Junya
Xi, Yuann
Wang, Qi
Wang, Runsheng
Novegil, Veronica
Altan, Mehmet
Cascone, Tina
Dasari, Arvind
Elamin, Yasir Y.
Fossella, Frank V.
Glisson, Bonnie S.
Lu, Charles S.
Negrao, Marcelo V.
Skoulidis, Ferdinandos
Vokes, Natalie
Cardnell, Robert J.
Wistuba, Ignacio I.
Wang, Jing
Heymach, John V.
Byers, Lauren A.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT218
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT218
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer
    Chen, Gigi
    Huynh, Minh
    Fehrenbacher, Lou
    West, Howard
    Lara, Primo N., Jr.
    Yavorkovsky, Leonid L.
    Russin, Michael
    Goldstein, Desiree
    Gandara, David
    Lau, Derick
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1401 - 1404
  • [22] High-grade neuroendocrine carcinoma of the lung: Comparative clinicopathological study of large cell neuroendocrine carcinoma and small cell lung carcinoma
    Sun, Lihua
    Sakurai, Shinji
    Sano, Takaaki
    Hironaka, Mitsugu
    Kawashima, Osamu
    Nakajima, Takashi
    PATHOLOGY INTERNATIONAL, 2009, 59 (08) : 522 - 529
  • [23] Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer
    Trafalis, Dimitrios T.
    Alifieris, Constantinos
    Stathopoulos, George P.
    Sitaras, Nikolaos
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 713 - 722
  • [24] Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer
    Dimitrios T. Trafalis
    Constantinos Alifieris
    George P. Stathopoulos
    Nikolaos Sitaras
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 713 - 722
  • [25] DareonTM-5: An open-label Phase II trial of BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas
    Gambardella, Valentina
    Greystoke, Alastair
    Reck, Martin
    Liu, Meiruo
    Mueller, Martha
    Duenzinger, Ulrich
    Bergsland, Emily B.
    Owonikoko, Taofeek
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [26] Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer
    Igawa, Satoshi
    Watanabe, Reiko
    Ito, Ichiro
    Murakami, Haruyasu
    Takahashi, Toshiaki
    Nakamura, Yukiko
    Tsuya, Asuka
    Kaira, Kyoichi
    Naito, Tateaki
    Endo, Masahiro
    Yamamoto, Nobuyuki
    Kameya, Toru
    LUNG CANCER, 2010, 68 (03) : 438 - 445
  • [27] Phase II Trial of NGR-hTNF and Doxorubicin in Relapsed Small Cell Lung Cancer (SCLC)
    Vigano, M.
    Cavina, R.
    Novello, S.
    Grassi, F.
    Santoro, A.
    Gregorc, V.
    Rossoni, G.
    Levra, M. G.
    Lambiases, A.
    Bordignon, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S623 - S623
  • [28] CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas
    Giuseppe Pelosi
    Michele Masullo
    Maria Elena Leon
    Giulia Veronesi
    Lorenzo Spaggiari
    Felice Pasini
    Angelica Sonzogni
    Antonio Iannucci
    Enrica Bresaola
    Giuseppe Viale
    Virchows Archiv, 2004, 445 : 449 - 455
  • [29] CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas
    Pelosi, G
    Masullo, M
    Leon, ME
    Veronesi, G
    Spaggiari, L
    Pasini, F
    Sonzogni, A
    Iannucci, A
    Bresaola, E
    Viale, G
    VIRCHOWS ARCHIV, 2004, 445 (05) : 449 - 455
  • [30] Pemetrexed (P) in relapsed small cell lung cancer (SCLC): Preliminary results of a phase II trial
    Raju, R. N.
    Neubauer, M. A.
    Smith, D. A.
    Richards, D. A.
    Asmar, L.
    Cunneen, J. L.
    Chen, R.
    Tai, D. F.
    Obasaju, C. K.
    Socinski, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345